Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mesoblast ADR Representing 10 Ord Shs MESO

Healthcare Biotechnology
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for... see more

Recent & Breaking News (NDAQ:MESO)

MESO Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Mesoblast Limited Investors of Class Action and Lead Plaintiff Deadline: December 7, 2020

Business Wire October 20, 2020

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mesoblast Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA October 19, 2020

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Mesoblast Limited of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 7, 2020 - MESO

Newsfile October 19, 2020

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mesoblast Limited (MESO)

Business Wire October 19, 2020

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Mesoblast Limited Investors of Important December 7 Deadline in Securities Class Action- MESO

Business Wire October 16, 2020

ROSEN, A LEADING LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Mesoblast Limited; Encourages Investors with Losses in Excess of $100K to Contact Firm - MESO

Business Wire October 15, 2020

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mesoblast Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA October 15, 2020

MESO ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of December 7, 2020 in the Class Action Filed on Behalf of Mesoblast Limited Limited Shareholders

Newsfile October 15, 2020

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mesoblast Limited (MESO)

Business Wire October 15, 2020

MESO Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Mesoblast Limited Shareholders of Class Action and Lead Plaintiff Deadline: December 7, 2020

GlobeNewswire October 15, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO

ACCESSWIRE IA October 14, 2020

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Mesoblast Limited of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 7, 2020 - MESO

Newsfile October 14, 2020

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Precigen, Royal Caribbean, and Mesoblast and Encourages Investors to Contact the Firm

GlobeNewswire October 14, 2020

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mesoblast Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA October 14, 2020

MESO Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Mesoblast Limited Investors of Class Action and Lead Plaintiff Deadline: December 7, 2020

ACCESSWIRE IA October 14, 2020

Notice of Lead Plaintiff Deadline for Shareholders in the Mesoblast Limited Class Action Lawsuit

Business Wire October 14, 2020

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mesoblast Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA October 13, 2020

Randomized Controlled Phase 3 Trial of Remestemcel-L for Reduced Mortality in COVID-19 Acute Respiratory Distress Syndrome Surpasses 50% Enrollment

GlobeNewswire October 13, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO

GlobeNewswire October 12, 2020

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Mesoblast Limited of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 7, 2020 - MESO

Newsfile October 12, 2020